Bcr-Abl regulates osteopontin transcription via Ras, PI-3K, aPKC, Raf-1, and MEK

Journal of Leukocyte Biology

Volumn 78, Issue 1, 2005, Pages 289-300

  Hickey, Fionnuala B ^a   England, Karen ^a   Cotter, Thomas G ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Cellular signaling; Chronic myeloid leukemia; Gene expression

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BCR ABL PROTEIN; COMPLEMENTARY DNA; ETOPOSIDE; FARNESYLTHIOSALICYLIC ACID; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLSERINE; PROTEIN KINASE C; RAF PROTEIN; RAS PROTEIN; RNA; UO 126;

ANIMAL CELL; APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; ENZYME ACTIVITY; ENZYME ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; IMMUNOBLOTTING; LEUKEMOGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL LINE; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; OSTEOPONTIN; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-RAF; RAS PROTEINS; RNA, MESSENGER; SIALOGLYCOPROTEINS; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 22144460122     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.1104655     Document Type: Article

References (66)

1. Rowley, J. D. (1978) Chromosome abnormalities in the acute phase of CML. Virchows Arch. B Cell Pathol. 29, 57-63.
2. Groffen, J., Stephenson, J. R., Heisterkamp, N., de Klein, A., Bartram, C. R., Grosveld, G. (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, Bcr, on chromosome 22. Cell 36, 93-99.
3. Lugo, T. G., Pendergast, A. M., Muller, A. J., Witte, O. N. (1990) Tyrosine kinase activity and transformation potency of Bcr-Abl oncogene products. Science 247, 1079-1082.
4. Daley, G. Q., Van Etten, R. A., Baltimore, D. (1990) Induction of chronic myelogenous leukemia in mice by the P210Bcr/Abl gene of the Philadelphia chromosome. Science 247, 824-830.
5. Kelliher, M. A., McLaughlin, J., Witte, O. N., Rosenberg, N. (1990) Induction of a chronic myelogenous leukemia-like syndrome in mice with v-Abl and BCR/ABL. Proc. Natl. Acad. Sci. USA 87, 6649-6653.
6. Shtivelman, E., Lifshitz, B., Gale, R. P., Roe, B. A., Canaani, E. (1986) Alternative splicing of RNAs transcribed from the human Abl gene and from the Bcr-Abl fused gene. Cell 47, 277-284.
7. Clark, S. S., McLaughlin, J., Timmons, M., Pendergast, A. M., Ben-Neriah, Y., Dow, L. W., Crist, W., Rovera, G., Smith, S. D., Witte, O. N. (1988) Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science 239, 775-777.
8. Salgia, R., Li, J. L., Ewaniuk, D. S., Pear, W., Pisick, E., Burky, S. A., Ernst, T., Sattler, M., Chen, L. B., Griffin, J. D. (1997) BCR/ABL induces multiple abnormalities of cytoskeletal function. J. Clin. Invest. 100, 46-57.
9. Mandanas, R. A., Boswell, H. S., Lu, L., Leibowitz, D. (1992) BCR/ABL confers growth factor independence upon a murine myeloid cell line. Leukemia 6, 796-800.
10. Puil, L., Liu, J., Gish, G., Mbamalu, G., Bowtell, D., Pelicci, P. G., Arlinghaus, R., Pawson, T. (1994) Bcr-Abl oncoproteins bind directly to activators of the Ras signaling pathway. EMBO J. 13, 764-773.
11. Bedi, A., Zehnbauer, B. A., Barber, J. P., Sharkis, S. J., Jones, R. J. (1994) Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83, 2038-2044.
12. Keeshan, K., Mills, K. I., Cotter, T. G., McKenna, S. L. (2001) Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia 15, 1823-1833.
13. Skorski, T., Bellacosa, A., Nieborowska-Skorska, M., Majewski, M., Martinez, R., Choi, J. K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T. O., Wasik, M. A., Tsichlis, P. N., Calabretta, B. (1997) Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3K/Akt-dependent pathway. EMBO J. 16, 6151-6161.
14. Hoover, R. R., Gerlach, M. J., Koh, E. Y., Daley, G. Q. (2001) Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene 20, 5826-5835.
15. Nieborowska-Skorska, M., Ratajczak, M. Z., Calabretta, B., Skorski, T. (1994) The role of c-Myc protooncogene in chronic myelogenous leukemia. Folia Histochem. Cytobiol. 32, 231-234.
16. Chai, S. K., Nichols, G. L., Rothman, P. (1997) Constitutive activation of JAKs and STATs in BCR-ABL-expressing cell lines and peripheral blood cells derived from leukemic patients. J. Immunol. 159, 4720-4728.
17. Hu, D. D., Lin, E. C., Kovach, N. L., Hoyer, J. R., Smith, J. W. (1995) A biochemical characterization of the binding of osteopontin to integrins α v β 1 and α v β 5. J. Biol. Chem. 270, 26232-26238.
18. Weber, G. F., Ashkar, S., Glimcher, M. J., Cantor, H. (1996) Receptor-ligand interaction between CD44 and osteopontin (η-1). Science 271, 509-512.
19. Chambers, A. F., Hota, C., Prince, C. W. (1993) Adhesion of metastatic, Ras-transformed NIH 3T3 cells to osteopontin, fibronectin, and laminin. Cancer Res. 53, 701-706.
20. Senger, D. R., Perruzzi, C. A., Papadopoulos-Sergiou, A., Van de Water, L. (1994) Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol. Biol. Cell 5, 565-574.
21. Butler, W. T. (1989) The nature and significance of osteopontin. Connect. Tissue Res. 23, 123-136.
22. Chiba, S., Okamoto, H., Kon, S., Kimura, C., Murakami, M., Inobe, M., Matsui, Y., Sugawara, T., Shimizu, T., Uede, T., Kitabatake, A. (2002) Development of atherosclerosis in osteopontin transgenic mice. Heart Vessels 16, 111-117.
23. Xie, Y., Sakatsume, M., Nishi, S., Narita, I., Arakawa, M., Gejyo, F. (2001) Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int. 60, 1645-1657.
24. Furger, K. A., Menon, R. K., Tuckl, A. B., Bramwelll, V. H., Chambers, A. F. (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr. Mol. Med. 1, 621-632.
25. Senger, D. R., Perruzzi, C. A., Gracey, C. F., Papadopoulos, A., Tenen, D. G. (1988) Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res. 48, 5770-5774.
26. Takeda, H., Matozaki, T., Takada, T., Noguchi, T., Yamao, T., Tsuda, M., Ochi, F., Fukunaga, K., Inagaki, K., Kasuga, M. (1999) PI 3-kinase γ and protein kinase C-ζ mediate RAS-independent activation of MAP kinase by a Gi protein-coupled receptor. EMBO J. 18, 386-395.
27. Gadeau, A. P., Campan, M., Millet, D., Candresse, T., Desgranges, C. (1993) Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arterioscler. Thromb. 13, 120-125.
28. Scatena, M., Almeida, M., Chaisson, M. L., Fausto, N., Nicosia, R. F., Giachelli, C. M. (1998) NF-κB mediates αvβ3 integrin-induced endothelial cell survival. J. Cell Biol. 141, 1083-1093.
29. Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G., Druker, B. J. (1997) CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90, 4947-4952.
30. Chambers, A. F., Behrend, E. I., Wilson, S. M., Denhardt, D. T. (1992) Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, Ras-transformed NIH 3T3 cells. Anticancer Res, 12, 43-47.
31. Sonoyama, J., Matsumura, I., Ezoe, S., Satoh, Y., Zhang, X., Kataoka, Y., Takai, E., Mizuki, M., Machii, T., Wakao, H., Kanakura, Y. (2002) Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. J. Biol. Chem. 277, 8076-8082.
32. Cortez, D., Stoica, G., Pierce, J. H., Pendergast, A. M. (1996) The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene 13, 2589-2594.
33. Beck Jr., G. R., Knecht, N. (2003) Osteopontin regulation by inorganic phosphate is ERK1/2-, protein kinase C-, and proteasome-dependent. J. Biol. Chem. 278, 41921-41929.
34. Schramm, K., Niehof, M., Radziwill, G., Rommel, C., Moelling, K. (1994) Phosphorylation of c-Raf-1 by protein kinase A interferes with activation. Biochem. Biophys. Res. Commun. 201, 740-747.
35. Lackey, K., Cory, M., Davis, R., Frye, S. V., Harris, P. A., Hunter, R. N., Jung, D. K., McDonald, O. B., McNutt, R. W., Peel, M. R., Rutkowske, R. D., Veal, J. M., Wood, E. R. (2000) The discovery of potent cRaf1 kinase inhibitors. Bioorg. Med. Chem. Lett. 10, 223-226.
36. Hall-Jackson, C. A., Eyers, P. A., Cohen, P., Goedert, M., Boyle, F. T., Hewitt, N., Plant, H., Hedge, P. (1999) Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. 6, 559-568.
37. Tuck, A. B., Hota, C., Wilson, S. M., Chambers, A. F. (2003) Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene 22, 1198-1205.
38. Akita, Y., Ohno, S., Konno, Y., Yano, A., Suzuki, K. (1990) Expression and properties of two distinct classes of the phorbol ester receptor family, four conventional protein kinase C types, and a novel protein kinase C. J. Biol. Chem. 265, 354-362.
39. Van Lint, J. V., Sinnett-Smith, J., Rozengurt, E. (1995) Expression and characterization of PKD, a phorbol ester and diacylglycerol-stimulated serine protein kinase. J. Biol. Chem. 270, 1455-1461.
40. Ono, Y., Fujii, T., Ogita, K., Kikkawa, U., Igarashi, K., Nishizuka, Y. (1989) Protein kinase C ζ subspecies from rat brain: its structure, expression, and properties. Proc. Natl. Acad. Sci. USA 86, 3099-3103.
41. Akimoto, K., Mizuno, K., Osada, S., Hirai, S., Tanuma, S., Suzuki, K., Ohno, S. (1994) A new member of the third class in the protein kinase C family, PKC λ, expressed dominantly in an undifferentiated mouse embryonal carcinoma cell line and also in many tissues and cells. J. Biol. Chem. 269, 12677-12683.
42. van Dijk, M. C., Hilkmann, H., van Blitterswijk, W. J. (1997) Platelet-derived growth factor activation of mitogen-activated protein kinase depends on the sequential activation of phosphatidylcholine-specific phospholipase C, protein kinase C-ζ and Raf-1. Biochem. J. 325, 303-307.
43. Zhou, G., Seibenhener, M. L., Woolen, M. W. (1997) Nucleolin is a protein kinase C-ζ substrate. Connection between cell surface signaling and nucleus in PC12 cells. J. Biol. Chem. 272, 31130-31137.
44. House, C., Kemp, B. E. (1987) Protein kinase C contains a pseudosubstrate prototope in its regulatory domain. Science 238, 1726-1728.
45. Selbie, L. A., Schmitz-Peiffer, C., Sheng, Y., Biden, T. J. (1993) Molecular cloning and characterization of PKC ι, an atypical isoform of protein kinase C derived from insulin-secreting cells. J. Biol. Chem. 268, 24296-24302.
46. Hirai, T., Chida, K. (2003) Protein kinase Cζ (PKCζ): activation mechanisms and cellular functions. J. Biochem. (Tokyo) 133, 1-7.
47. Neshat, M. S., Raitano, A. B., Wang, H. G., Reed, J. C., Sawyers, C. L. (2000) The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. MoL. Cell. Biol. 20, 1179-1186.
48. Wang-Rodriguez, J., Urquidi, V., Rivard, A., Goodison, S. (2003) Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status. Breast Cancer Res. 5, R136-R143.
49. Angelucci, A., Festuccia, C., D'AndrEa, G., Teti, A., Bologna, M. (2002) Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators. Biol. Chem. 383, 229-234.
50. Schneider, S., Yochim, J., Brabender, J., Uchida, K., Danenberg, K. D., Metzger, R., Schneider, P. M., Salonga, D., Holscher, A. H., Danenberg, P. V. (2004) Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin. Cancer Res. 10, 1588-1596.
51. Saeki, Y., Mima, T., Ishii, T., Ogata, A., Kobayashi, H., Ohshima, S., Ishida, T., Tabunoki, Y., Kitayama, H., Mizuki, M., Katada, Y., Asaoku, H., Kitano, M., Nishimoto, N., Yoshizaki, K., Maeda, M., Kon, S., Kinoshita, N., Uede, T., Kawase, I. (2003) Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Br. J. Haematol. 123, 263-270.
52. Renault, M. A., Jalvy, S., Belloc, I., Pasquet, S., Sena, S., Olive, M., Desgranges, C., Cadeau, A. P. (2003) AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells. Circ. Res. 93, 674-681.
53. Zhang, J., Takahashi, K., Takahashi, F., Shimizu, K., Ohshita, F., Kameda, Y., Maeda, K., Nishio, K., Fukuchi, Y. (2001) Differential osteopontin expression in lung cancer. Cancer Lett. 171, 215-222.
54. Denhardt, D. T., Mistretta, D., Chambers, A. F., Krishna, S., Porter, J. F., Raghuram, S., Rittling, S. R. (2003) Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin. Exp. Metastasis 20, 77-84.
55. Atkins, K. B., Simpson, R. U., Somerman, M. J. (1997) Stimulation of osteopontin mRNA expression in HL-60 cells is independent of differentiation. Arch. Biochem. Biophys. 343, 157-163.
56. Chang, P. L., Tucker, M. A., Hicks, P. H., Prince, C. W. (2002) Novel protein kinase C isoforms and mitogen-activated kinase kinase mediate phorbol ester-induced osteopontin expression. Int. J. Biochem. Cell Biol. 34, 1142-1151.
57. Moses, S., Franzen, A., Lovdahl, C., Hultgardh-Nilsson, A. (2001) Injury-induced osteopontin gene expression in rat arterial smooth muscle cells is dependent on mitogen-activated protein kinases ERK1/ERK2. Arch. Biochem. Biophys. 396, 133-137.
58. Xie, Z., Pimental, D. R., Lohan, S., Vasertriger, A., Pligavko, C., Colucci, W. S., Singh, K. (2001) Regulation of angiotensin II-stimulated osteopontin expression in cardiac microvascular endothelial cells: role of p42/44 mitogen-activated protein kinase and reactive oxygen species. J. Cell. Physiol. 188, 132-138.
59. Murray, N. R., Fields, A. P. (1997) Atypical protein kinase C ι protects human leukemia cells against drug-induced apoptosis. J. Biol. Chem. 272, 27521-27524.
60. Jamieson, L., Carpenter, L., Biden, T. J., Fields, A. P. (1999) Protein kinase Cι activity is necessary for Bcr-Abl-mediated resistance to drug-induced apoptosis. J. Biol. Chem. 274, 3927-3930.
61. Gustafson, W. C., Ray, S., Jamieson, L., Thompson, E. A., Brasier, A. R., Fields, A. P. (2004) Bcr-Abl regulates protein kinase Cι (PKCι) transcription via an Elk1 site in the PKCι promoter. J. Biol. Chem. 279, 9400-9408.
62. Mas, V. M., Hernandez, H., Plo, I., Bezombes, C., Maestre, N., Quillet-Mary, A., Filomenko, R., Demur, C., Jaffrezou, J. P., Laurent, G. (2003) Protein kinase Cζ mediated Raf-1/extracellular-regulated kinase activation by daunorubicin. Blood 101, 1543-1550.
63. Akimoto, K., Takahashi, R., Moriya, S., Nishioka, N., Takayanagi, J., Kimura, K., Fukui, Y., Osada, S., Mizuno, K., Hirai, S., Kazlauskas, A., Ohno, S. (1996) EGF or PDGF receptors activate atypical PKCλ through phosphatidylinositol 3-kinase. EMBO J. 15, 788-798.
64. Murray, N. R., Jamieson, L., Yu, W., Zhang, J., Gokmen-Polar, Y., Sier, D., Anastasiadis, P., Gatalica, Z., Thompson, E. A., Fields, A. P. (2004) Protein kinase Cι is required for Ras transformation and colon carcinogenesis in vivo. J. Cell Biol. 164, 797-802.
65. Pal, S., Datta, K., Khosravi-Far, R., Mukhopadhyay, D. (2001) Role of protein kinase Cζ in Ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression. J. Biol. Chem. 276, 2395-2403.
66. Fedorov, Y. V., Jones, N. C., Olwin, B. B. (2002) Atypical protein kinase Cs are the Ras effectors that mediate repression of myogenic satellite cell differentiation. Mol. Cell. Biol. 22, 1140-1149.